Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT07296484

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose other
Phase
Phase 2
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Sparrow Pharmaceuticals (from the registry)
Registry
  • NCT NCT07296484
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07296484. Randomized; quadruple masking; primary purpose other. Start 2025-11-29 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Acronym
CAPTAIN-T2D
Condition
Cortisol Excess
Intervention (Drug)
clofutriben
Intervention (Drug)
Placebo
Lead sponsor
Sparrow Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07296484
Content hash
6b95e69d694b814baabec8b355172560e8b7917d36de94089ba3d95d7ea3a23d